Mergers & Acquisitions ·
Pluri Inc. agrees to acquire 50% of Zeo ScientifiX in strategic merger expected Q4 2026
ZEOXZeo ScientifiX, Inc.
Zeo ScientifiX and Pluri Inc. entered into a definitive strategic agreement under which Pluri will issue shares representing 50% of ZEO's issued and outstanding common stock immediately following closing. The transaction combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales infrastructure. Pluri gains exclusive U.S. rights to its CellaV aesthetic product line through the partnership. Following closing, ZEO’s financial results are expected to be consolidated into Pluri’s statements. The deal is not subject to stockholder approval and is expected to close in the fourth quarter of 2026, pending customary conditions including ancillary agreements and regulatory approvals. Zeo ScientifiX operates as a biopharmaceutical company integrating regenerative biologics research, development, and manufacturing with commercial operations.